Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HAE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHaemonetics restructures reporting segments, merging Plasma and Blood Center into Apheresis
Filed June 5, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
medium
Effective Q1 fiscal 2027, Haemonetics will combine its Plasma and Blood Center segments into a single Apheresis segment and rename Hospital to MedSurg, aligning external reporting with internal management structure.
Item 8.01 view on EDGAR → -
medium
Company posted nine quarters of historical financials (Q1 FY2024-Q4 FY2026) restated under the new segment structure to enable year-over-year comparisons going forward.
Item 8.01 view on EDGAR → -
medium
Fiscal 2027 guidance has been recast into the new segment framework but is not being reaffirmed or updated; actual guidance updates expected during Q1 FY2027 earnings call.
Item 8.01 view on EDGAR →
Summary
Haemonetics announced a reorganization of its reporting segments to better reflect how management runs the business. Starting in the first quarter of fiscal 2027, the company will report results under two segments instead of three: Apheresis (combining the former Plasma and Blood Center units) and MedSurg (the renamed Hospital segment).
This is primarily an accounting presentation change rather than an operational restructuring. For retail investors, the key takeaway is that future quarterly results will look different on the surface, but the underlying business operations remain unchanged. The company has helpfully provided nine quarters of historical data restated under the new structure, allowing for clean comparisons.
The fiscal 2027 guidance numbers remain the same but are now allocated across the new segments. Watch the Q1 fiscal 2027 earnings call for any substantive guidance updates and management commentary on whether the segment consolidation reflects deeper strategic shifts in how the company views its blood management and hospital product lines.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Beginning with the first quarter of fiscal 2027, the previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg.
The company is consolidating two segments (Plasma and Blood Center) into one new segment called Apheresis, and renaming its Hospital segment to MedSurg. This restructuring changes how the company reports financial results externally to better match internal management structure. The changes take effect in the first quarter of fiscal year 2027.
Added in current filing · verify on EDGAR →
the Company has posted to the Investor Relations page on its website (www.haemonetics.com) a supplemental presentation outlining the reporting changes, including quarterly historical reconciliations from the first quarter of fiscal year 2024 through the fourth quarter of fiscal year 2026
The company has published historical financial data restated under the new segment structure, covering nine quarters from Q1 FY2024 through Q4 FY2026. This allows investors to compare future results on an apples-to-apples basis with historical performance under the new reporting framework.
Added in current filing · verify on EDGAR →
the company has provided a recast of its previously issued fiscal 2027 guidance in the new segment structure. The Company is not reaffirming or updating its previously issued fiscal year 2027 guidance.
The company has translated its existing fiscal 2027 guidance into the new segment structure but explicitly states it is not reaffirming or updating the guidance itself. This means the numerical targets remain unchanged but are now presented under the new Apheresis and MedSurg segment names. Any actual guidance updates will come during the Q1 FY2027 earnings call.
Event · Item 9.01 — Financial Statements and Exhibits
Haemonetics filed an 8-K attaching a press release issued June 5, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release issued by Haemonetics Corporation on June 5, 2026.
The 8-K references a press release issued on June 5, 2026, attached as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature and materiality of the event cannot be determined from this 8-K alone. Investors must review Exhibit 99.1 to understand what was announced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify